PNAS paper on potential breast cancer treatment retracted

The authors of a 2009 study in the Proceedings of the National Academy of Sciences (PNAS) have retracted the paper, which found a particular molecule could make breast tumors respond to a drug to which they’re not normally susceptible.

The paper — which has been cited five times, according to Thomson Scientific’s Web of Knowledge — was the subject of a fair amount of press coverage, although the molecule is not yet in clinical trials. In a Reuters story, lead author Caroline Ford said of the alleged tamoxifen-sensitizing compound, Foxy-5:

“It flips the switch basically,” Ford said in a telephone interview. “It makes breast cancer cells respond to tamoxifen in women who cannot be treated with the drug,” she added. “If you don’t have that molecule you can’t get tamoxifen because there is no target.”

According to the retraction notice, signed by all three of the study’s authors: Continue reading PNAS paper on potential breast cancer treatment retracted

Best of Retractions Part III: Whatever can go wrong …

Paging Dr. Murphy.

In July, the editors of Cancer Biology & Therapy published a retraction remarkable for its scope. Apparently, nearly everything dishonest authors can do to doctor a manuscript, these authors did.

The paper, “Overexpression of transketolase protein TKTL1 is associated with occurrence and progression in nasopharyngeal carcinoma,” initially appeared on the journal’s website in January 2008. It came out in print three months later, in the April issue, and has been cited 8 times since, according to Thomson Scientific’s Web of Knowledge.

The authors were Song Zhang, Jian Xin Yue,  Ju Hong Yang, Peng Cheng Cai and Wei Jia Kong, of Huazhong University of Science and Technology in Hubei, China. It will be quite clear why we listed all those authors in a moment. Continue reading Best of Retractions Part III: Whatever can go wrong …

Cell retraction for bogus images in genetics paper reveals another, in Journal of Molecular Biology

Call it bad luck, but the journal Cell has been victimized again by image manipulation. For the second time this month, the publication has retracted a paper whose authors acknowledged that one of them had played around with the figures.

Published in August 2009, the paper, “Population-Level Transcription Cycles Derive from Stochastic Timing of Single-Cell Transcription,” has been cited 16 times, according to Thomson Scientific’s Web of Knowledge. It purported to show using computer modeling that

transcriptional cycling, i.e., periodic assembly of transcription factors and their cofactors and the resulting cyclical accumulation of mRNA, may stem from stochastic timing and sequential activation of transcription in individual cells.

The authors, from several European institutions, presented experimental data to back up their computer model, including multiple figures. Some of those, they now admit, were fabricated — to the point where the whole paper collapsed: Continue reading Cell retraction for bogus images in genetics paper reveals another, in Journal of Molecular Biology

Science plays two — a retraction, and concern issued about genetics papers

It’s a busy week at Science. The journal is retracting a controversial paper about which it had previously expressed doubts, and has published an “Expression of Concern” about another article that looks like it might be headed for the same fate.

First, the retraction.

The move involves an October 2009 paper, on which we’ve previously posted, by European researchers who claimed to have made a major advance in the ability to watch how enzymes behave in cells — thereby giving scientists a new tool for monitoring the function of genes.

But back in December, Science editor Bruce Alberts issued this “Expression of Concern” about the research: Continue reading Science plays two — a retraction, and concern issued about genetics papers

Previously questioned Nature paper on innate immunity retracted

courtesy Nature

Last week, we noted a Nature editorial in which the journal came clean about its higher-than-average number of retractions this year — four. What we missed was the fact that the fourth retraction of the year also appeared in last week’s issue.

The retraction, of a paper called “The large-conductance Ca2+-activated K+ channel is essential for innate immunity,” reads (link to the author’s homepage added): Continue reading Previously questioned Nature paper on innate immunity retracted

Blood posts “notice of concern” over second Wagers-Mayack paper

A day after an up and coming Harvard stem cell scientist retracted a Nature paper, Blood has issued a notice of concern about another paper by the same group, published in August 2008, the Boston Globe reports. Such notices often, but not always, precede retractions.

According to the notice for “Osteolineage niche cells initiate hematopoietic stem cell mobilization”: Continue reading Blood posts “notice of concern” over second Wagers-Mayack paper

Highly cited Harvard stem cell scientist retracts Nature paper

courtesy Nature

Amy Wagers, an up and coming stem cell researcher at Harvard who made a name for herself as a postdoc early by questioning the work of others, has retracted a January 2010 paper she co-authored in Nature. According to the retraction:

Three of the authors (J.L.S., F.S.K. and A.J.W.) wish to retract this Article after a re-examination of the publication raised serious concerns with some of the reported data. These concerns have undermined the authors’ confidence in the support for the scientific conclusions reported, specifically the role of osteopontin-positive niche cells in the rejuvenation of haematopoietic stem cells in aged mice. Although this matter is under further review, these authors wish to retract the paper in its entirety, and regret any adverse consequences that may have resulted from the paper’s publication. The retraction has not been signed by Shane R. Mayack, who maintains that the results are still valid.

What’s going on at Haematologica? Journal double-publishes three different studies

Sometimes, studies are so nice, you want to print them twice. But when that happens three times within a year, well, maybe it’s not so nice. Consider the following three retractions, which appeared on a single page of Haematologica last month.

One:

The Haematologica Production Office erroneously double-published the article entitled “P39/Tsugane cells are a false cell line contaminated with HL-60 cells and are not suitable for mechanistic studies in myelodysplastic syndromes” by David P. Steensma. Haematologica. 2010 Feb 23. [Epub ahead of print] with doi:10.3324/haematol.2009.022988 . This article must therefore be considered as retracted, as the correct version of the same article has been correctly published on July 1, 2010, as doi:10.3324/haematol.2010.022988. Haematologica sincerely apologizes to the authors and the readers for this mistake.

Two: Continue reading What’s going on at Haematologica? Journal double-publishes three different studies

Gene therapy researcher Savio Woo retracts two more papers

courtesy Mount Sinai School of Medicine

Mount Sinai School of Medicine researcher Savio Woo, whom Retraction Watch reported last week has already retracted four papers from major journals as two postdocs have been fired from his lab, has retracted two more from Molecular Therapy: The Journal of the American Society of Gene Therapy.

The two papers, both from 2007, were Continue reading Gene therapy researcher Savio Woo retracts two more papers

Update on gene therapy researcher Savio Woo retractions: Two post-docs dismissed for fraud

More on the case of Savio Woo, the New York gene therapy researcher who, as Retraction Watch reported  this week, had several papers pulled by noted journals.

Two of Woo’s post-doctoral fellows at Mount Sinai School of Medicine were dismissed for “research misconduct,” said Ian Michaels, a spokesman for the institution. According to Michaels:

When Dr. Savio L C Woo came to suspect that two post-doctoral fellows in his laboratory may have engaged in research misconduct he notified the Mount Sinai Research Integrity Office. Mount Sinai immediately initiated institutional reviews that resulted in both post-doctoral fellows being dismissed for research misconduct. At no time were there allegations that Dr. Woo had engaged in research misconduct. As part of its review, the investigation committee looked into this possibility and confirmed that no research misconduct could be attributed to Dr. Woo, who voluntarily retracted the papers regarding the research in question. Mount Sinai reported the results of its investigations to the appropriate government agencies and continues to cooperate with them as part of its commitment to adhere to the highest standards for research integrity.

We have plenty of other questions for Mount Sinai about the details of the investigation—including when the post-docs were let go, which Michaels declined to answer—and will update when we learn more.